Effects of erythropoietin administration in training athletes and possible indirect detection in doping control
- PMID: 10331881
- DOI: 10.1097/00005768-199905000-00003
Effects of erythropoietin administration in training athletes and possible indirect detection in doping control
Abstract
Purpose: This study investigated the effects of repeated subcutaneous injection of rHuEpo (50 IU x kg(-1)) in athletes and proposes a method based on the measurement in blood samples of the sTfR/serum protein ratio to determine if the observed values of this marker are related to rHuEpo abuse.
Methods: Serum erythropoietin concentrations, and hematological and biochemical parameters were evaluated, during treatment and for 25 d posttreatment in nine training athletes. Moreover, the effect of rHuEpo administrations on the maximum oxygen uptake (VO2max) and ventilatory threshold (VT) of these athletes was also studied. Threshold values for sTfr and the sTfr/serum protein ratio were determined from 233 subjects (185 athletes, 15 athletes training at moderately high altitude, and 33 subjects living at >3000 m).
Results: Significant changes in reticulocytes, hemoglobin (Hb) concentration, hematocrit (Hct), sTfr, and sTfr/serum proteins were observed during and after rHuEpo treatment. The maximal heart rate of 177 beats x min(-1) at the beginning of the study was significantly higher than the value of 168 beats x min(-1) after 26 d of rHuEpo administration. Compared with the values measured at baseline, the VT measured after rHuEpo administration occurred at a statistically significant high level of oxygen uptake.
Conclusions: When oxygen uptake measured at the VT was expressed as a percentage of V02 max, the values obtained were also significantly higher. The increased values of Tfr and sTfr/serum proteins, respectively, above 10 microg x mL(-1) and 153, indicated the probable intake of rHuEpo.
Similar articles
-
Effect of rhEPO administration on serum levels of sTfR and cycling performance.Med Sci Sports Exerc. 2000 Jul;32(7):1238-43. doi: 10.1097/00005768-200007000-00009. Med Sci Sports Exerc. 2000. PMID: 10912888 Clinical Trial.
-
Effect of physical fitness and endurance exercise on indirect biomarkers of recombinant erythropoietin misuse.Int J Sports Med. 2007 Jan;28(1):9-15. doi: 10.1055/s-2006-924029. Epub 2006 Jun 26. Int J Sports Med. 2007. PMID: 16804802
-
Effects of EPO on Blood Parameters and Running Performance in Kenyan Athletes.Med Sci Sports Exerc. 2019 Feb;51(2):299-307. doi: 10.1249/MSS.0000000000001777. Med Sci Sports Exerc. 2019. PMID: 30188362
-
Pharmacokinetics/pharmacodynamics of recombinant human erythropoietins in doping control.Sports Med. 2003;33(4):301-15. doi: 10.2165/00007256-200333040-00004. Sports Med. 2003. PMID: 12688828 Review.
-
Monitoring recombinant human erythropoietin abuse among athletes.Biosens Bioelectron. 2015 Jan 15;63:86-98. doi: 10.1016/j.bios.2014.06.068. Epub 2014 Jul 8. Biosens Bioelectron. 2015. PMID: 25058943 Review.
Cited by
-
The ergogenic effect of recombinant human erythropoietin on VO2max depends on the severity of arterial hypoxemia.PLoS One. 2008 Aug 20;3(8):e2996. doi: 10.1371/journal.pone.0002996. PLoS One. 2008. PMID: 18714372 Free PMC article.
-
Haemoglobin mass and running time trial performance after recombinant human erythropoietin administration in trained men.PLoS One. 2013;8(2):e56151. doi: 10.1371/journal.pone.0056151. Epub 2013 Feb 13. PLoS One. 2013. PMID: 23418527 Free PMC article. Clinical Trial.
-
Detection of DNA-recombinant human epoetin-alfa as a pharmacological ergogenic aid.Sports Med. 2002;32(2):125-42. doi: 10.2165/00007256-200232020-00004. Sports Med. 2002. PMID: 11817997 Review.
-
Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit.Br J Clin Pharmacol. 2013 Jun;75(6):1406-21. doi: 10.1111/bcp.12034. Br J Clin Pharmacol. 2013. PMID: 23216370 Free PMC article.
-
Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes : a population approach.Clin Drug Investig. 2003;23(3):167-79. doi: 10.2165/00044011-200323030-00003. Clin Drug Investig. 2003. PMID: 23340923
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous